CSL (OTCMKTS:CSLLY) Shares Gap Up – Here’s Why

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) shares gapped up before the market opened on Tuesday. The stock had previously closed at $33.35, but opened at $35.64. CSL shares last traded at $34.37, with a volume of 1,765 shares traded.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Zacks Research raised CSL from a “strong sell” rating to a “hold” rating in a research note on Friday, August 7th. Royal Bank Of Canada raised shares of CSL from a “hold” rating to a “moderate buy” rating in a research note on Tuesday, September 15th. One analyst has rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold”.

CSL Stock Performance

The business’s 50-day simple moving average is $30.58 and its 200-day simple moving average is $24.28. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.21 and a quick ratio of 0.97.

About CSL

CSL Limited (OTCMKTS:CSLLY) is an Australia-based biotechnology company that develops, manufactures and delivers medicines and vaccines. Its products address a range of serious and chronic conditions, including immune deficiencies, bleeding disorders, respiratory diseases, influenza and iron deficiency.

Through CSL Behring, the company produces plasma-derived and recombinant therapies, including immunoglobulins, albumin and treatments for hemophilia and hereditary angioedema. CSL also operates CSL Seqirus, a major influenza vaccine business that supplies seasonal and pandemic influenza vaccines, as well as other specialty products.